AMD gene discovered

Article

The SERPING1 gene code influences the likelihood of developing age-related macular degeneration (AMD), according to study results published online ahead of print by The Lancet.

The SERPING1 gene code influences the likelihood of developing age-related macular degeneration (AMD), according to study results published online ahead of print by The Lancet.

Professor Andrew Lotery, FRCOphth of Southampton General Hospital, Southampton, UK and colleagues conducted low-density screening of the genes of patients with AMD (n=479), and compared them with the genes of control patients (n=479). The team used 93 single nucleotide polymorphisms (SNPs) to look at 32 genes previously known to be relevant in the development of AMD, and then conducted high-density screening to confirm initial results. To validate results, the study was also replicated in a US case series (AMD, n=248; control, n=252).

The team found that variation in the SERPING1 gene - specifically the SNP variant rs2511989, located with intron six of the gene, although five other SNP variants were also implicated - demonstrated a highly significant association with AMD. This was the only association found between AMD and all of the genes tested, and the US cohort of the study corroborated these findings.

Thus the team conjectured that variation within the SERPING1 gene may influence vulnerability to AMD development, most likely because these variants disable the gene’s role in inhibiting complement component 1 (C1) which, in part, defends against AMD.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.